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Abstract: The chapter examined solid lipid nanoparticles (SLN) and microemulsions, chosen as carriers
of drugs, administered in vivo to be transported to the central nervous system. Drugs of different
structures and for different therapies have been studied such as doxorubicin SLN stealth and nonstealth
administered in rats by intravenous route, apomorphine SLN administered in rats by duodenal route,
melatonin SLN administered by transdermal and oral routes in humans, and apomorphine microemulsion
administered by transdermal route in Parkinson’s patients. The pharmacokinetics of the drug, followed in
most studies, put in evidence that the many important pharmacokinetic parameters were notably
improved versus the drug alone or in a commercial formulation.
Keywords: solid lipid nanoparticles; microemulsions; drug delivery system; central nervous system
Introduction
The brain homeostasis is of primary importance
for survival so that specific interfaces, also
referred to as barriers, tightly regulate the
exchange between the peripheral blood circula-
tion and the cerebrospinal fluid (CSF) circulatory
system. These barriers are represented by the
choroid plexus epithelium, the arachnoid epithe-
lium, and the blood–brain barrier (BBB). The
concentration and clearance of endogenous and
exogenous molecules, essential for the normal
brain functions or dangerous because of their toxi-
city, are strictly regulated by the anatomic and
physiologic features of each barrier (Abbott,
2002; Segal, 2000).
The presence of the BBB is certainly the most
critical issue encountered in brain drug delivery.
Among the possible strategies to deliver therapeu-
tic molecules into the brain, namely, intracerebral,
intraventricular, and intravascular delivery, the
latest represents the most reliable one because of
its potential efficacy, safety, and compliance
(Silva, 2007).
Brain capillaries, differently from the peripheral
capillaries, present no fenestrae, a low amount of
pinocytosis vesicles and particular tight junctions
also known zonula occludens. Tight junctions are
structures that form a narrow and continuous seal
surrounding each endothelial and epithelial cell at
the apical border and are at strictly regulating the
movements the molecules through the paracellular
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pathway. These structures, together with the brain
endothelial cells, make an almost impermeable
barrier for drugs administered through the
peripheral circulation (Kniesel & Wolburg, 2000;
Lapierre, 2000).
A further contribution to the peculiar BBB
functions is given by the periendothelial structures
represented by astrocytes, pericytes, and the basal
membrane (Balahanov & Dore-Duffy, 1998; Lay
& Kuo, 2005).
The presence of BBB transport systems further
complicates the scenario. In fact, these transpor-
ters may assist or hinder the drug delivery to the
brain. The carrier-mediated transport may be able
to shuttle drugs or prodrugs into the brain in
therapeutic concentrations, mimicking nutrients
or endogenous compounds (Conford & Hyman,
1999; Pardrige, 1998).
Unfortunately, the presence of active efflux
transporters to the BBB also limits the therapeutic
efficacy of drugs virtually able to access the brain.
The P-glycoprotein (P-gp) is an ATP-dependent
drug transport protein present at the apical mem-
branes of different epithelial cell types including
those forming the BBB.
Recently, it has been demonstrated, either in
vitro or in vivo, that BBB P-gp can prevent the
accumulation of many molecules including a vari-
ety of drugs in the brain (Stouch & Gudmundsson,
2002), and P-gp inhibition has been proposed as a
possible strategy to enhance the drug penetration
(Skinkel, 1999).
Different strategies have been studied for the
delivery of drugs to the brain. Indeed most part of
the small drug molecules and of large molecules
such as recombinant proteins or gene-based mole-
cules are not able to penetrate the BBB and many
efforts have been spent in the previous years
toward delivery and targeting of drugs to the
brain (de Boer & Gaillard, 2007). Many investiga-
tions have been carried out in the previous years
to improve brain tumors therapy with nanoparti-
culates; there are less number of studies regarding
colloidal carriers of drugs for neurological diseases
or of diagnostics. Liposomes, polymeric nanopar-
ticles, and solid lipid nanoparticles (SLN) have
been studied, with different approaches, and the
problems of overcoming the BBB.
In this chapter, we consider SLN and microe-
mulsions as carriers for the delivery only of drugs
active on the central nervous system (CNS). In
particular, examining drugs used for therapy in
neurological diseases, as many times their admin-
istration gives problems, such as high amount of
drug administered by parenteral route, short half-
life, high hydrophilicity, and poor transport
through the BBB. The aim of all the researchers
is to study if some improvements in pharmacoki-
netic parameters in laboratory animals and/or in
humans could be achieved using colloidal formu-
lations; the review considers studies on SLN and
microemulsions carrying only drugs active on
CNS.
Solid lipid nanoparticles
Different approaches are followed for the SLN
preparation.
They can be prepared by high-pressure homo-
genization at elevated or low temperatures, via
warm microemulsions, by solvent emulsification–
evaporation–diffusion, by high-speed stirring, and/
or sonication (Muller, Kader, & Gohla, 2000).
Here we refer only about SLN carrying drugs
active on CNS (at brain level).
SLN carrying the lipophilic antipsychotic drug
clozapine were prepared by hot homogenization
followed by ultrasonication method. Clozapine
has a very poor bioavailability (Manjunath &
Venkateswarlu, 2005). The SLN were adminis-
tered by intravenous (IV) and duodenal routes
to Swiss albino mice. For the intravenous admin-
istration, stearylamine was entrapped with cloza-
pine in SLN; the area under curve (AUC) in the
brain increased up to 2.91-fold the one of cloza-
pine suspension.
The same authors (Manjunath & Venkates-
warlu, 2006) developed SLN as carriers of the
highly lipophilic drug nitrendipine, using different
triglycerides for the lipid matrix, soy lecithin, and
Poloxamer 188. Positive and negative charged
nitrendipine SLN were also produced and then
examined to explore the influence of the charge
on oral bioavailability. The different kinds of SLN
were administered by IV and intraduodenal
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routes to rats; pharmacokinetic parameters of
nitrendipine SLN were examined, tissue distribu-
tion studies were carried out in Swiss albino mice,
against that of a nitrendipine suspension. Follow-
ing IV administration nitrendipine-loaded SLN
were found to be taken up to a greater extent in
tested organs than nitrendipine suspension. The
AUC and MRTAU3 of nitrendipine SLN were higher
than those of nitrendipine suspension especially in
brain and heart. Positively charged SLN were bet-
ter taken up by the brain and moderately taken up
by the heart. Reticuloendothelial system (RES)
organs such as liver and spleen were compared
with the ones after nitrendipine suspension admin-
istration. The higher levels of the drug were main-
tained for over 6 h in confrontAU4 to only 3 h with
nitrendipine suspension.
SLN were investigated for their ability to deli-
ver quinine dihydrochloride for the management
of cerebral malaria (Gupta, Jain, & Jain, 2007).
Quinine was incorporated in SLN and successively
coupling of SLN with transferrin (Tf) was
achieved by a cross-linker. IV administration of
Tf-conjugated SLN enhanced the brain uptake of
quinine in confront to the SLN loaded of quinine
alone.
In order to enhance the delivery of atazanavir, a
HIV protease inhibitor, spherical SLN carrying
the drug were tested at first using a well-charac-
terized human brain microvessel endothelial cell
line (hCMEC/D3). Cell viability experiments
demonstrated that SLN exhibit no toxicity on
hCMEC/D3 cells up to a concentration corre-
sponding to 200 nM of the drug. Delivery of 3H-
atazanavir by SLN led to a significantly higher
accumulation by the endothelial cell monolayer
as compared to the drug aqueous solution (Chat-
topadhyay, Zastre, Wong, Wu, & Bendayan,
2008).
The transport in situ of lipid nanoparticles to the
brain was evaluated by Koziara, Lockman, Allen,
and Mumper (2003); the lipidic nanoparticles were
prepared by warm microemulsion precursors fol-
lowed by hot homogenization technique. Their
components were emulsified wax (E wax) or Brij
72 as matrix, and water and Brij 78 as surfactant.
The warm microemulsion was cooled upon stir-
ring and the lipid SLN were obtained and
homogenized. The SLN were labelled with 3H
cetyl alcohol. The transport of the nanoparticles
was measured by an “in situ” rat brain perfusion
method; significant uptake of SLN was obtained .
suggesting CNS uptake. The same group studied
also the effect that the addition of a thiamine
ligand to NP AU5s, obtained by microemulsion as pre-
cursors, causes association with the BBB thiamine
transporter (Lockman et al., 2003).
Muller and coworkers studied the preferential
adsorption of blood protein onto intravenously
injected particulate carriers from different origins
(Luck, Paulke, Schroder, Blunk, & Muller, 1998);
in particular, Apolipoprotein E (Apo E) AU6on the
surface of P80-coated SLN after their incubation
in human plasma citrate. Delivery to the brain
using nanoparticulate drug carriers in combination
with the targeting principles of “differential pro-
tein adsorption” has been proposed (Dehouck
et al., 1997). The Pathfinder technology (Muller
& Schmidt, 2002) exploits proteins present in the
blood which absorb onto the surface of intrave-
nously injected carriers for targeting nanoparticles
to the brain. Apo E is one of such targeting mole-
cules for the delivery of nanoparticles to the
endothelial cells of the BBB. Apo E can play an
important role in the transport of lipoprotein into
brain via the low-density lipoprotein receptor pre-
sent on the BBB. Atoquavone (Muller & Keck,
2004; Scholler et al., 2001) is a drug poorly
adsorbed after oral administration, showing poor
therapeutic efficacy against toxoplasma encepha-
litis (TE). Nanocrystals of the drug were pro-
duced, their surface was modified with Tween 80
leading to in vivo preferential absorption of Apo
E; the nanosuspension was IV administered to a
murine model of TE, obtaining the disappearance
of parasites and of cysts at dose 10-fold smaller
than the one of atoquavone administered by oral
route.
Solid lipid nanoparticles from warm
microemulsions
SLN can be achieved from warm microemulsions.
Warm microemulsions are prepared at tem-
perature ranging from 60 AU7C to 80C by using
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melted lipids (such as triglycerides/fatty acids) as
oil, surfactants such as lecithin, and cosurfactants
(such as short-chain carboxylates, biliarAU8 salts); the
warm microemulsions are subsequently dispersed
in cold water. The nanodroplets of warm micro-
emulsion, using this procedure, become SLN; they
are successively washed by tangential flow filtra-
tion. SLN are spherical in shape and with a narrow
size distribution .The zeta potential is normally
high (30/40mV) being positive or negative
depending on the starting formulation.
Hydrophilic and lipophilic molecules (drugs or
diagnostics) can be incorporated in SLN using
different methods.
SLN are able to carry drugs of different struc-
ture and lipophilicity, such as cyclosporine A
(Ugazio, Cavalli, & Gasco, 2002), paclitaxel
(Cavalli, Caputo, & Gasco, 2000), doxorubicin
(Fundaro, Cavalli, Bargoni, Vighetto, & Gasco,
2000), tobramycin (Cavalli et al., 2003), short-
chain fatty acidsAU9 (Dianzani et al., 2006), peptides
(Morel, Cavalli, & Gasco, 1996), antisense oligo-
nucleotides (Brioschi et al., 2008), and melatonin
(MT) (Rezzani et al., 2009). Also diagnostic com-
pounds such as iron oxides (Pereira, 2003AU10 ) have
been incorporated into SLN.
SLN can be internalized within 2–3min into all
the tested cell lines (Miglietta, Cavalli, Bocca,
Gabriel, & Gasco, 2000; Serpe et al., 2006); admi-
nistered by duodenal route and are targeted to
lymph (Bargoni et al., 1998). SLN stealth can
also be prepared to avoid their recognition by
the RES, thus prolonging their residence time
(Podio, 2001AU11 ). SLN drug, unloaded or loaded,
stealth/or nonstealth, are transported through the
BBB (Podio, 2001; Zara et al., 2002).
Drug-loaded solid lipid nanoparticles
In the late 1990s SLN were proposed for brain
drug targeting by several groups (Yang, Zhu, Lu,
& Liang, 1999; Zara et al., 1999), which studied
the pharmacokinetics of two anticancer agents:
camptothecin and doxorubicin. After oral and IV
administration, they observed drug accumulation
into the brain.
Both stealth and nonstealth stearic acid
unloaded labelled SLN were found in rat CSF
20min after IV administration even though low
amount of radioactivity was found in the CSF
samples collected from cysterna magna (Podio,
Zara, Carazzone, Cavalli, & Gasco, 2000).
When the same kind of SLN were loaded with
doxorubicin, significantly higher drug concentra-
tions were found in the brain of the animals trea-
ted with stealth SLN as compared to nonstealth
SLN and doxorubicin solution. The overall plasma
pharmacokinetics of stealth and nonstealth SLN
provided to be significantly different from that of
the doxorubicin solution (Fundaro et al., 2000).
R-apomorphine (10,11-dihydroxyapomorphine)
is a well-known potent short-acting dopamine ago-
nist at D1 and D2 dopamine receptors and it was
proposed as an antiparkinsonian drug more than a
century ago. It significantly reduces the severity
and duration of “off” periods and it is able to
reverse bradykinesia when administered alone.
Despite these favorable clinical effects, the drug’s
clinical use is somewhat limited by its pharmaco-
kinetic profile: short half-life (30min), rapid
clearance from the plasma, lack of storage and
retention in brain regions, poor oral bioavailabil-
ity (5%), and first-pass hepatic metabolism are
significant limitations to chronic oral administra-
tion. Our group evaluated a new formulation of
apomorphine in SLN (submitted data for publish-
ing AU12); the study was designed to investigate the
pharmacokinetics and biodistribution of apomor-
phine incorporated in SLN, injected orally or
intravenously in rats.
In vitro the release over time of apomorphine
from the SLN dispersion was almost linear After
IV administration the peak plasma concentration
was higher after apomorphine solution adminis-
tration than after apomorphine SLN. However,
the total area under curve (AUCtot) was nonsigni-
ficantly different after SLN than apomorphine
solution. The terminal half-life was significantly
longer following apomorphine SLN.
Following intraduodenal administration we
found that the Cmax and AUCtot were significantly
higher with apomorphine SLN compared to apo-
morphine solution; on the contrary, the clearance
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was shorter after apomorphine solution than after
the SLN formulation.
In the brain the apomorphine concentration
was significantly higher 30min after apomorphine
SLN IV administration versus solution; it was
detected only at 4 h after apomorphine SLN
injection.
After duodenal administration the drug was
detectable in brain only at 30min after apomor-
phine SLN administration. No drug was found
neither at 4 h nor at 24 h after injection of either
apomorphine SLN or the solution.
Furthermore, the free drug concentration was
measured in human plasma and we showed that
the release started after the absorption of the
apomorphine SLN. We also measured the free
apomorphine concentration in human blood over
time. The amounts in question are relatively low,
but may be sufficient to expect clinical effects
when administered to parkinsonian patients.
After apomorphine solution administration, the
amounts of apomorphine determined in the
plasma were by far lower than those from SLN,
confirming previous studies on the duodenal
administration of drug loaded and unloaded SLN
(Fig. 1).
In order to furnish a general model for SLN-
based delivery systems of drugs devoid of favor-
able pharmacokinetics, we have recently
incorporated MT in SLN (MT-SLN). MT has
been chosen for our in vivo study because of its
safeness in humans even at high dosages.
MT is a hormone produced by the pineal gland
at night, involved in the regulation of circadian
rhythms. For clinical purposes (mainly disorders
of the sleep–wake cycle and insomnia in the
elderly), exogenous MT administration should
mimic the typical nocturnal endogenous MT
levels, but its pharmacokinetics is not favorable
due to its short half-life of elimination (DeMuro,
Nafziger, Blask, Menhinick, & Bertino, 2000;
Mallo et al., 1990). The pharmacokinetics of MT-
SLN has been examined in humans after adminis-
tration by oral and transdermal route (Priano
et al., 2007). Three kinds of freeze-dried MT-
SLN containing different amounts of MT were
prepared and characterized: (a) MT-SLN: MT =
1.8% for in vitro experiments (average diameter:
85 nm, polydispersity index = 0.135); (b) MT-SLN:
MT = 2% for transdermal application (average
diameter = 91 nm, polydispersity index = 0.140);
and (c) MT-SLN: MT = 4.13% for oral route
(average diameter = 111 nm, polydispersity index
= 0.189).
In vitro, MT-SLN produced a flux of MT of 1
mg/h/cm2 through hairless mice skin, following a
pseudo-zero-order kinetics (45) AU13. At the same time,
in vivo study produced very interesting results,
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Fig. 1. Plasma levels of free apomorphine and total apomorphine after duodenal administration of apomorphine solution or
apomorphine SLN in rats.
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confirming in humans that SLN can act as a reser-
voir that allows a constant and prolonged release
of the included drugs (Peira et al., 2003). MT
(3mg) incorporated in SLN was orally adminis-
tered at 8.30 a.m. to seven healthy subjects; for
control purposes, 1 week later the same subjects
received orally a standard formulation of MT at
the same dose (3mg) and again at 8.30 a.m. Com-
pared to the MT standard solution, Tmax observed
after MT-SLN administration was delayed of
about 20min, while mean AUC and mean half-
life of elimination were significantly higher
(respectively 169,944.7+ 64,954.4 pg/mL×hour
vs. 85,148.4+ 50,642.6 pg/mL×hour, p= 0.018;
and 93.1+ 37.1min vs. 48.2+ 8.9min, p= 0.009).
Even more, standard formulation and MT-SLN
after oral administration produced similar peak
plasma levels of MT, even if delayed of about
half an hour in the case of MT-SLN. More inter-
estingly, detectable and clinically significant MT
plasma levels after MT-SLN oral administration
were maintained for a longer period of time, sug-
gesting that SLN orally administered to humans
can yield a sustained release of the incorporated
drug, a feature that could be particularly useful for
molecules, such as MT, characterized by unfavor-
able kinetics (Priano et al., 2007). Previous studies
in laboratory animals indicated a probable target-
ing of SLN — either drug-loaded or unloaded —
to lymph, after duodenal administration (Bargoni
et al., 1998). Similarly, the significantly longer
half-life of MT observed in the study of Priano
et al. (2007) may suggest a targeting of MT-SLN to
human lymph, even though the capsules used to
administer SLN were not gastro-resistant. In fact,
MT half-life of elimination has been calculated in
about 40min after an intravenous bolus and fol-
lowing oral administration low bioavailability and
rapid clearance from plasma have been shown,
primarily due to a marked first-pass hepatic meta-
bolism. Moreover, pharmacokinetic analysis fol-
lowing transdermal administration of MT-SLN
demonstrated that plasma levels of MT similar to
those produced by oral administration may be
achieved for more than 24 h (50). In 10 healthy
subjects, SLN incorporating MT were adminis-
tered transdermally by applying a patch at 8.30
a.m. and leaving it in place for 24 h. In this deliv-
ery system, MT absorption and elimination were
slow (mean half-life of absorption = 5.3+ 1.3 h;
mean half-life of elimination = 24.6+ 12.0 h) so
that MT plasma levels above 50 pg/mL were main-
tained for at least 24 h (Figs. 2 and 3). Tolerability
of MT-SLN administered transdermally or by oral
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Fig. 2. MT plasma profile in humans after MT (¤) and MT-SLN (&) oral administration.
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route was good and no adverse effect occurred,
apart from a predictable mild somnolence and
transient erythema after gel application. This
means that, at least at the doses used in that
study (45), SLN administration via the oral or
transdermal routes is safe.
In this context, we also tested transdermal MT-
SLN for three consecutive nights in five patients
suffering from delayed sleep phase syndrome
(unpublished data), confirming the safeness of
this formulation. Due to the small sample, how-
ever, the tendency of clinical benefits was present
but statistical significance could not be reached, so
that further investigations in larger samples are
needed in order to evaluate the impact of this
new formulation in clinical practice.
However, these very favorable results, obtained
in humans administering MT-loaded SLN, clearly
suggest that SLN can be considered effective in
vivo delivery systems that could be suitably
applied to different drugs, and in particular to
those requiring prolonged high plasma levels but
that have unfavorable pharmacokinetics. Finally,
it must be stressed that, since doses and concen-
trations of drugs included in SLN can be varied,
different plasma level profiles could be obtained,
thus disclosing new chances for sustained delivery
systems adaptable to a variety of clinical condi-
tions (Priano et al., 2007).
Suitability of SLN to convey drugs into CNS is
also confirmed by studies regarding baclofen
included in SLN. Intrathecal baclofen administra-
tion represents the reference treatment for spasti-
city of spinal or cerebral origin. Nevertheless,
surgical involvement together with risk of infec-
tion or catheter dysfunction may limit the number
of potentially treatable patients (Dario & Tomei,
2004; Perot & Almeida-Silveira, 1994). In order to
explore alternative and efficacious routes of
administration, we studied a new pharmaceutical
preparation characterized by SLN incorporating
baclofen (baclofen-SLN) (submitted data for pub-
lishing AU14). Baclofen concentration, after reconstitu-
tion with water of freeze-dried SLN, was 1.7mg/
mL. Groups of Wistar rats were injected intraper-
itoneally with physiological solution and unloaded
SLN at 10mL/kg (control groups), with baclofen-
SLN (baclofen-SLN group), and baclofen solution
(baclofen-sol group) at increasing dosages of 2.5,
5, 7.5, 8.5, and 10mg/kg. At different times up to
the fourth hour, efficacy testing was performed by
means of H-reflex, while behavioral characteriza-
tion was obtained using two scales validated for
motor symptoms due to spinal lesions and seda-
tion in rat models (Nemethy, Paroli, Williams-
Russo, & Blanck, 2002; Tsunoda, Kuang, Tolley,
Whitton, & Fujinami, 1998). Rats were sacrificed
for detecting baclofen concentration in blood and
tissue. Compared to baclofen-sol and control
group, H/M amplitude curve after baclofen-SLN
injection was characterized by a dose-dependent
reduction at the first and second hours, so con-
firming efficacy, and a rebound increase at the
fourth hour, indicating an unexpected belated
spinal hyperexcitability (Fig. 4). Similarly, baclo-
fen-SLN effect on behavioral scales was stronger
compared to baclofen-sol group, with the maxi-
mum effects obtained at the first hour. Moreover,
clinical effects were detectable after low dosages
of baclofen-SLN (2.5mg/kg) but only after higher
dosages of baclofen-sol (7.5mg/kg). After 4 h from
the injection, only the rats treated with the higher
dosages of baclofen-SLN still presented clinical
signs consisting in sedation (8.5mg/kg) or com-
plete paralysis and piloerection (10mg/kg). On
the whole, these data suggest a dose-dependent
modulation of spinal reflex excitability, which is
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not so evident after administration of standard
formulation of baclofen. Nevertheless, important
cortical effects were also present. Clinical data
were related with plasma and tissue concentra-
tions. In fact, after 2 and 4 h only baclofen-SLN
administration produced measurable baclofen
plasma concentrations, with an almost linear
decrease of baclofen appreciable for 4 h. On the
contrary, undetectable amount of baclofen in
plasma were noticed 2 h after administration of
baclofen-sol. In brain, both the two formulations
(baclofen in solution and in SLN) gave a maxi-
mum after 2 h but concentrations after SLN were
almost twice the ones after solution. This last data
might be due partly to the free drug already
released and to baclofen-SLN overcoming the
BBB. We realize that for clinical purposes this
effect of baclofen-SLN is unwishedAU15 , as it is respon-
sible for sedation. However, baclofen-sol injec-
tions also produced sedation, even if weaker and
corresponding to lower plasma concentrations,
compared to baclofen-SLN. In conclusion, higher
spinal and cortical effects of baclofen-SLN, com-
pared to equivalent dosages of baclofen-sol, seem
attributable to higher and more prolonged con-
centrations of drugs in plasma and brain.
As previously noted, unloaded SLN adminis-
tered by duodenal route are targeted to lymph
and the incorporated drug can be partly distribu-
ted in the brain; moreover, SLN can also be
prepared stealth for increasing their residence
time (Bargoni et al., 1998; Fundaro et al., 2000;
Podio, 2001; Zara et al., 2002). Other new studies
will be directed toward a duodenal administration
of baclofen-SLN stealth, not only for prolonging
their residence time but also to target them to
lymph, enhancing their bioavailability. Further
research should also be directed toward the opti-
mization of dosages and concentrations of baclo-
fen included in SLN, in order to preserve the
prolonged antispastic effect, peculiar of this new
formulation, but devoid of clinically significant
cortical effects.
Solid lipid nanoparticles as potential diagnostics
Superparamagnetic iron oxides are classified as
contrast agents for magnetic resonance imaging
(MRI). They are able to affect the water relaxa-
tion times T1 and T2; their ability in altering such
properties is quantified by the parameter relaxiv-
ity. Iron oxides are able to affect preferentially the
T2 relaxation times of tissues (and are called
T2-relaxing agents) while paramagnetic contrast
agents such as Gd complexes affect mainly
T1 and are called T1-relaxing agents.
Iron oxides are insoluble in water; therefore, to
be clinically used they must be transformed in
modified colloids while their magnetic properties
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Fig. 4. H/M amplitude ratios after baclofen-solution (a) and after baclofen-SLN (b), at increasing doses, compared to control animal
group. p < 0.05; p < 0.01; p < 0.001.
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should remain unchanged. The surface of the iron
oxide nanoparticles can be modified, covering
them by hydrophilic macromolecules; such as dex-
tran in the case of Endorem.
A research was performed in order to know
whether SLN can load iron oxides and whether
they are able to reach the brain. Two different
SLN, SLN-FeA and SLNBAU16 containing iron oxides
were prepared from warm microemulsions and
studied at first in vitro (1). The comparison of
Fe-SLN was performed with Endorem. Both the
Fe-SLN preparations showed relaxometric prop-
erties similar to the ones of Endorem. The good
T2-relaxation-enhancing properties allow an in
vivo study of their distribution by MRI. Fe-
SLNB, at the higher Fe concentration, were
administered IV to rats; the comparison was
performed with Endorem. Images obtained
after Endorem IV administration show early
modification, but soon return to baseline; these
findings are consistent with short Endorem
retention time in blood. Results from SLN-FeB
show a different behavior. For each part of the
brain, maximal SSAU17 is reached in the last images
(135min after administration). SS increase from
the first to the last acquisition. This study shows
that after inclusion in SLN, Endorem becomes a
new type of contrast agent: Endorem is taken by
the liver and does not cross the BBB, while
Endorem containing SLN-FeB shows CNS
uptake. This means that SLN-Fe kinesis is
related to SLN and not to their iron oxide con-
tent as already seen.
Microemulsions
Microemulsions are transparent, thermodynami-
cally stable dispersions of water and oil, usually
stabilized by a surfactant and a cosurfactant. They
contain particles smaller than 0.1 mm. Microemul-
sions are often defined as thermodynamically
stable liquid solutions; the stability of microemul-
sions is a consequence of the ultralow interfacial
tension between the oil and water phases. A clear
distinction exists between microemulsion and
coarse emulsions. The latter are thermodynami-
cally unstable, droplets of their dispersed phase
are generally larger than 0.1mm and consequently
their appearance is normally milky rather than
transparent.
The limits in the use of microemulsions in the
pharmaceutical field are chiefly from the need of
all the components to be acceptable, particularly
surfactants and cosurfactants — the amounts of
surfactants and cosurfactants required to form
microemulsions are usually higher than those
required for emulsions.
Recently, apomorphine was incorporated into
microemulsions to study whether they are a feasi-
ble vehicle for transdermal transport of this drug.
In the preparatory in vitro study (Peira, Scolari, &
Gasco, 2001), two different microemulsions whose
components were all biocompatible were studied:
the concentration of apomorphine was 3.9% in
each. Since apomorphine is highly hydrophilic, to
increase its lipophilicity, apomorphine–octanoic
acid ion pairs were formed. At pH 6.0, log Papp
of apomorphine increased from 0.3 in the absence
of octanoic acid to log Papp = 2.77 for a molar ratio
1:2.5 (apomorphine: octanoic acid). The flux of
drug from the two thickened microemulsions
through hairless mouse skin was, respectively,
100 and 88mg/h/cm2. The first formulation, having
the higher flux, was chosen for in vivo administra-
tion to Parkinson’s patients.
For the in vivo study, 21 patients with idiopathic
Parkinson’s disease who presented long-term
L-DOPA syndrome, motor fluctuations and pro-
longed “off” periods were selected (Priano et al.,
2004). Here, 10 g of apomorphine hydrochloride
(3.9%), included in microemulsion for transder-
mal delivery (Apo-MTD), was applied to a 100
cm2 skin area on the chest; the area was delimited
by 1-mm-thick biocompatible foam tape and cov-
ered with a polyester-based membrane and an
occlusive membrane to prevent evaporation. In
these conditions, a single layer of microemulsion
(1mm thick) was directly in contact with the skin
surface and acted as a reservoir of apomorphine.
Apo-MTD was applied at 8.00 a.m. and left for 12
h. In all patients, except two, apomorphine was
detected in blood samples after a variable lag
time. Pharmacokinetic analysis revealed that epi-
cutaneous–transdermal apomorphine absorption
was rapid (mean half-life of absorption = 1.03 h)
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with a variability among patients (half-life of
absorption, SD=1.39 h). Mean Cmax was above
the therapeutic range (mean Cmax = 42.81+ 11.67
ng/mL), with a mean Tmax of 5.1+ 2.24 h. Ther-
apeutic concentrations of apomorphine were
reached after a mean latency of 45min (range
18–125), and stable concentrations, above the
therapeutic range, continued for as long as Apo-
MTD was maintained in place. At the 12th hour,
Apo-MTD was removed, and the apomorphine
plasma concentration then decreased at a rate
comparable to that described for subcutaneous
administration (mean half-life of elimination
equal to 10.8+ 1.93 h). Cmax and AUC showed
good correlations with the reduction of “off” per-
iods duration and with the improvement of clinical
scores evaluating motor performances (r values
ranging form 0.49 to 0.56, with p values ranging
from 0.02 to 0.04). Apo-MTD overall tolerability
was good: systemic side effects were similar to
those caused by subcutaneous apomorphine injec-
tion (sleepiness, mild orthostatic hypotension, and
transient nausea), and in the case of nausea, they
were strictly related to the highest plasma level of
apomorphine. Moreover, regarding local side
effects, the large majority of patients (71.4%) pre-
sented a transient mild erythema at the site of
Apo-MTD application, with a complete regression
within 48 h, whereas only in two cases the
erythema lasted more than 3 days and required
local therapy. This study clearly demonstrated
that in most Parkinson’s patients Apo-MTD is
absorbed by the epicutaneous–transdermal route.
This result is in contrast with other reports, where
the transdermal route did not produce detectable
plasma levels of apomorphine, or in which no apo-
morphine was transported passively through the skin
(Gancher, Nutt, & Woodward, 1991; van der Geest,
van Laar, Gubbens-Stibbe, Boddé, & Danhof,
1997). Probably, this difference was mainly due to
the peculiar pharmaceutical preparation used. Even
if pharmacokinetic parameters are variable, Apo-
MTD demonstrated the feasibility of providing ther-
apeutic apomorphine plasma levels for much longer
periods of time than previously tested apomorphine
preparations (several hours), allowing a more con-
stant dopaminergic stimulation. These results are
encouraging and Apo-MTD might become of
clinical value in some parkinsonian patients suffering
from uncontrolled “wearing-off” and prolonged
“off” phenomena. On the contrary, because of the
lag time of about 1h before therapeutic concentra-
tions are reached, Apo-MTDmay not be the “ideal”
preparation for rapid relief of “off” periods.
Since Apo-MTD was found to provide constant
drug release over several hours, other studies have
been addressed to its use for the nocturnal sleep
disorders of Parkinson’s patients. Twelve parkin-
sonian patients underwent standard polysomno-
graphy on basal condition and during one night
treatment with Apo-MTD (applied to 100 cm2
from 10 p.m. until 8 a.m.; Priano et al., 2003).
Sleep analysis during APO-MTD treatment in
comparison to basal condition showed very favor-
able findings: 16% increment of total sleep time,
12% increment of sleep efficiency, 16% increment
of stage 3 and 4 nonrapid eye movement
(NREM), 15% reduction of periodic limb move-
ments index, 22% reduction of arousal index, and
23% reduction of the “cycling alternating pattern”
rate, an objective measure of disruption and frag-
mentation of NREM sleep. Pharmacokinetic ana-
lysis confirmed the absorption of apomorphine
and the maintenance of therapeutic plasma levels
for several hours (mean Cmax = 31.8+ 9.7 ng/mL;
mean Tmax = 3.1+ 1.6 h; mean half-life of absorp-
tion = 1.2+ 1.4 h; mean half-life of elimination =
8.8+ 1.9 h). On the whole, this study confirmed
that APO-MTD in Parkinson’s disease might be
able to reduce nocturnal anomalous movements,
akinesia, and rigidity, and might be efficacious for
reducing the instability of sleep maintenance typi-
cal of parkinsonian sleep.
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